drugset / Trial / NCT02205541

Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU

NCT02205541

Phase 3 Completed 100 enrolled University Hospital, Toulouse
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators aim to perform the first controlled randomized prospective study using ECZ in pediatric STEC-HUS. This is of great interest as there is still no efficient specific therapy in that potentially devastating disease. Furthermore, published data concerning the use of ECZ in STEC-HUS are controversial, reflecting statistical bias in retrospective or uncontrolled studies, thus emphasizing the need for prospective studies.

Timeline

Start
2015-06
Primary completion
2018-06
Completion
2018-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 300 mg Intravenous